ProMIS Neurosciences Soars on First Nasdaq Trading Day
Newly uplisted biotech, ProMIS Neurosciences (Nasdaq: PMN)(TSX: PMN), soared on its first day of trading on Nasdaq, on Friday 8 July, closing up 44%.
ProMIS is focused on developing antibody therapeutics for neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease and multisystem atrophy (MSA). Neurodegenerative diseases are ultimately fatal and have no cure.
- ProMIS enjoyed a stellar first day of trading and has performed solidly during the week;
- The company reached a high of $13.20 and has seen a price increase of 57% over the past month;
- ProMIS expects to enter the clinic in early 2023 with its first drug candidate, PMN310 to address one of the world’s largest unmet medical needs, Alzheimer’s disease;
- CEO, Eugene Williams, thanked Canadian and US investors for their support and said the company’s mission is to “make significant contributions to treating neurodegenerative diseases.”
ProMIS rang the closing bell at Nasdaq on Wednesday 13 July. The company has a proud Canadian history and is dual listed on the Toronto Stock Exchange and Nasdaq.